EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

A randomized phase II study of fulvestrant with or without ganetespib in patients with endocrine-resistant metastatic breast cancer

Albert Grinshpun iD, Adrienne G Waks, Jingxin Fu iD, Patrick Kurnia iD, Hao Guo, Tianyu Li, McKenna Moore, Molly DiLullo iD, Ashka Patel, Luke Whitesell iD, Stefan Atanasov, Ann H Partridge iD und 9 weitere

The Oncologist · 07.10.2026 · 31 (11)

DOI: 10.1093/oncolo/oyag414 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, online erschienen am 14.10.2026. Verfasst von Albert Grinshpun und 20 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA 02215, United States. Hauptthemen laut MEDLINE: Breast Neoplasms, Triazoles, Fulvestrant, Drug Resistance, Neoplasm. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Synta Pharmaceuticals, ICRF Clinical Research Career Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative metastatic breast cancer (MBC) have limited effective treatment options. Heat shock protein 90 (HSP90) regulates estrogen receptor stability and function; its inhibition has been proposed as a strategy to overcome endocrine resistance. Ganetespib is a second-generation HSP90 inhibitor with demonstrated anti-tumor activity in preclinical breast cancer models.

Methods

In this randomized phase II study, 50 patients with HR+ MBC previously treated with endocrine therapy were randomized 1:2 to fulvestrant alone (n = 15) or fulvestrant with ganetespib (n = 35), respectively. Median age was 53 years. Fulvestrant was administered at standard dosing; ganetespib (200 mg/m2) was given intravenously on days 1, 8, and 15 of each 28-day cycle. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival and safety/tolerability.

Results

Median PFS was similar between arms (3.7 vs 3.6 months; log-rank P = .79). Toxicity was higher with ganetespib, with substantially increased diarrhea (97% vs 7%) and nausea (63% vs 40%). Exploratory genomic analysis of on-treatment biopsies (n = 13) showed ESR1 mutations were enriched among patients without clinical benefit, while all patients with clinical benefit exhibited a Luminal A transcriptional subtype. Tumors lacking clinical benefit showed enrichment of proliferative and cell cycle–associated transcriptional programs.

Conclusions

Adding ganetespib to fulvestrant did not improve clinical outcomes and increased toxicity in endocrine-resistant HR+ MBC. Our findings support the hypothesis that ESR1 alterations and proliferative transcriptional activity contribute to established endocrine resistance, limiting the therapeutic impact of HSP90 inhibition in this setting. Clinical trial registration number NCT01560416 (ClinicalTrials.gov)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTriazolesFulvestrantDrug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedAdultAgedNeoplasm MetastasisHSP90 Heat-Shock Proteins

Stichwörter der Autor:innen

endocrine-resistantfulvestrantganetespibhormone receptor–positivemetastatic breast cancer

Substanzen

TriazolesFulvestrantSTA 9090HSP90 Heat-Shock Proteins

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston, MA 02215, United States.
  • Shaare Zedek Medical Center and Hebrew University, Jerusalem, 9103102, Israel.
  • Harvard Medical School, Boston, MA 02115, United States.
  • Whitehead Institute for Biomedical Research, Cambridge, MA 02142, United States.
  • Yale Cancer Center, New Haven, CT 06520, United States.
  • Yale School of Medicine, New Haven, CT 06510, United States.

ORCID-Profile: Albert Grinshpun, Jingxin Fu, Patrick Kurnia, Molly DiLullo, Luke Whitesell, Ann H Partridge, Erica L Mayer, Ian E Krop, Sandro Santagata, Myles Brown, Rinath Jeselsohn, Nancy U Lin

Förderung

  • Synta Pharmaceuticals
  • ICRF Clinical Research Career Development

Zitieren

APA

Grinshpun, A., Waks, A. G., Fu, J., Kurnia, P., Guo, H., Li, T., Moore, M., DiLullo, M., Patel, A., Whitesell, L., Atanasov, S., Partridge, A. H., Mayer, E. L., Krop, I. E., Santagata, S., Brown, M., Winer, E. P., Reeder-Hayes, K., Anders, C., …, & Lin, N. U. (2026). A randomized phase II study of fulvestrant with or without ganetespib in patients with endocrine-resistant metastatic breast cancer. The Oncologist, 31(11). https://doi.org/10.1093/oncolo/oyag414

Vancouver

Grinshpun A, Waks AG, Fu J, Kurnia P, Guo H, Li T, et al. A randomized phase II study of fulvestrant with or without ganetespib in patients with endocrine-resistant metastatic breast cancer. The Oncologist. 2026;31(11). doi:10.1093/oncolo/oyag414

BibTeX
@article{Grinshpun2026,
  author = {Grinshpun, Albert and Waks, Adrienne G and Fu, Jingxin and Kurnia, Patrick and Guo, Hao and Li, Tianyu and Moore, McKenna and DiLullo, Molly and Patel, Ashka and Whitesell, Luke and Atanasov, Stefan and Partridge, Ann H and Mayer, Erica L and Krop, Ian E and Santagata, Sandro and Brown, Myles and Winer, Eric P and Reeder-Hayes, Katherine and Anders, Carey and Jeselsohn, Rinath and Lin, Nancy U},
  title = {A randomized phase II study of fulvestrant with or without ganetespib in patients with endocrine-resistant metastatic breast cancer},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {11},
  doi = {10.1093/oncolo/oyag414}
}
Kostenlos starten →